These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26859221)

  • 1. The role of biologicals in intestinal transplantation.
    Pascher A; Atanasov G
    Curr Opin Organ Transplant; 2016 Apr; 21(2):171-7. PubMed ID: 26859221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologicals in the prevention and treatment of intestinal graft rejection: The state of the art Biologicals in Intestinal Transplantation.
    Karmi N; Uniken Venema WTC; van der Heide F; Festen EAM; Dijkstra G
    Hum Immunol; 2024 Jul; 85(4):110810. PubMed ID: 38788483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The microbiome and its implications in intestinal transplantation.
    Kroemer A; Elsabbagh AM; Matsumoto CS; Zasloff M; Fishbein TM
    Curr Opin Organ Transplant; 2016 Apr; 21(2):135-9. PubMed ID: 26761420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolutionary experience with immunosuppression in pediatric intestinal transplantation.
    Bond GJ; Mazariegos GV; Sindhi R; Abu-Elmagd KM; Reyes J
    J Pediatr Surg; 2005 Jan; 40(1):274-9; discussion 279-80. PubMed ID: 15868597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-HLA Antibodies May Accelerate Immune Responses After Intestinal and Multivisceral Transplantation.
    Gerlach UA; Lachmann N; Ranucci G; Sawitzki B; Schoenemann C; Pratschke J; Dragun D; Pascher A
    Transplantation; 2017 Jan; 101(1):141-149. PubMed ID: 27495766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Donor-Specific Antibodies in Intestinal Transplantation: Experience at the University of California Los Angeles and Literature Review.
    Cheng EY; Kaneku H; Farmer DG
    Clin Transpl; 2014; ():153-9. PubMed ID: 26281140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Present prospects and future perspectives of intestinal and multivisceral transplantation.
    Vianna RM; Mangus RS
    Curr Opin Clin Nutr Metab Care; 2009 May; 12(3):281-6. PubMed ID: 19357509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targets on B-cells to prevent and treat antibody-mediated rejection in organ transplantation. Present and Future.
    Galián JA; Mrowiec A; Muro M
    Expert Opin Ther Targets; 2016 Jul; 20(7):859-67. PubMed ID: 26695424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in allograft monitoring after intestinal transplantation.
    Lauro A; Marino IR; Matsumoto CS
    Curr Opin Organ Transplant; 2016 Apr; 21(2):165-70. PubMed ID: 26741111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Status of liver and gastrointestinal transplantation at the University of Miami.
    Weppler D; Khan R; Fragulidis GP; Nery JR; Ricordi C; Tzakis AG
    Clin Transpl; 1996; ():187-201. PubMed ID: 9286568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation.
    Garcia M; Weppler D; Mittal N; Nishida S; Kato T; Tzakis A; Ruiz P
    Transplant Proc; 2004 Mar; 36(2):323-4. PubMed ID: 15050146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 receptor signaling disruption prevents cardiac allograft deterioration in mice.
    Iida S; Omoto K; Kanemitsu I; Setoguchi K; Ishida H; Tanabe K; Suzuki T; Tashiro Y; Kishimoto H; Abe R
    Exp Clin Transplant; 2012 Aug; 10(4):375-85. PubMed ID: 22758208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impacts of donor-specific anti-HLA antibodies and antibody-mediated rejection on outcomes after intestinal transplantation in children.
    Petit LM; Rabant M; Canioni D; Suberbielle-Boissel C; Goulet O; Chardot C; Lacaille F
    Pediatr Transplant; 2017 Mar; 21(2):. PubMed ID: 28084679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of positive flow cytometry crossmatch on outcomes of intestinal/multivisceral transplantation: role anti-IL-2 receptor antibody.
    Kubal CA; Mangus RS; Vianna RM; Lobashevsky A; Mujtaba MA; Higgins N; Beduschi T; Fridell JA; Tector AJ
    Transplantation; 2013 May; 95(9):1160-6. PubMed ID: 23435456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Xenotransplantation and ABO incompatible transplantation: the similarities they share.
    Galili U
    Transfus Apher Sci; 2006 Aug; 35(1):45-58. PubMed ID: 16905361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor-specific human leukocyte antigen antibodies in intestinal transplantation.
    Kaneku H; Wozniak LJ
    Curr Opin Organ Transplant; 2014 Jun; 19(3):261-6. PubMed ID: 24811437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-2 antagonists: the European perspective.
    Platz KP; Braun F; Fändrich F; Kremer B; Mueller AR
    Transplant Proc; 2005 May; 37(4):1783-4. PubMed ID: 15919465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of the de novo production of anti-HLA antibodies following intestinal and multivisceral transplantation.
    Gerlach UA; Lachmann N; Sawitzki B; Arsenic R; Neuhaus P; Schoenemann C; Pascher A
    Transpl Int; 2014 Mar; 27(3):280-9. PubMed ID: 24279605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The transcription factor, T-bet, primes intestine transplantation rejection and is associated with disrupted mucosal homeostasis.
    Ranganathan S; Ashokkumar C; Ningappa M; Schmitt L; Higgs BW; Sindhi R
    Transplantation; 2015 Apr; 99(4):890-4. PubMed ID: 25340608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.